Announcement of the Board of Directors resolution
of the convening of the 2022 Annual
Shareholders' Meeting.
Date of events
2022/03/22
To which item it meets
paragraph 17
Statement
1.Date of the board of directors resolution:2022/03/22
2.General shareholders' meeting date:2022/06/10
3.General shareholders' meeting location:
International Conference Hall, Development Center for Biotechnology.
(1F, Building B, No.101, Lane.169, Kangning St., Xizhi Dist.,
New Taipei City.)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):
Physical shareholders meeting.
5.Cause for convening the meeting I.Reported matters:
(1)Report the business results of 2021.
(2)Audit Committee's review report.
(3)Report accumulated losses reaching one-half of paid-in capital
and execution of the improvement plan of business operations for
the fourth quarter of 2021.
(4)Report the status of the private placement of securities.
(5)Remuneration policy for the directors of 2021.
6.Cause for convening the meeting II.Acknowledged matters:
(1)Accept 2021 financial statements and business report.
(2)Ratification of the 2021 deficit offset proposal.
7.Cause for convening the meeting III.Matters for Discussion:
(1)Amendment to the company's Articles of Incorporation.
(2)Amendment to the Procedures for Acquisition or Disposal
of Assets.
(3)Amendment to the Rules of Procedure for
Shareholder Meetings.
(4)Adoption of the Issuance of Employee Restricted
Stock Awards.
(5)Approval of Private Placement of Securities.
8.Cause for convening the meeting IV.Election matters:
Election Fifth Term of Board Directors.
9.Cause for convening the meeting V.Other Proposals:
Proposal to Release the Prohibition on Directors or
Representatives of Directors from Participation in
Competitive Business.
10.Cause for convening the meeting VI.Extemporary Motions:None.
11.Book closure starting date:2022/04/12
12.Book closure ending date:2022/06/10
13.Any other matters that need to be specified:
(1) According to article 172-1 and 192-1 of Company Law,
if any shareholder holding 1% or more of the total number of
outstanding shares would like to propose in this general
shareholders' meeting or submit the candidate list for
Director, the company will receive such proposed proposition
from 2022/04/01 to 2022/04/11. Please submit the document
in written form to the company before 5pm on April 11, 2022.
The address of proposition receiving office: No.168, Sec.1,
Shengyi Rd., Zhubei City, Hsinchu County.(Department of Finance).
(2) Shareholders may exercise their rights through the electronic
voting system. The electronic voting period is from May 11, 2022
to June 7, 2022.
Attachments
Original Link
Original Document
Permalink
Disclaimer
EirGenix Inc. published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 14:11:06 UTC.
EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.